The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The safety of SAR405838 alone355 or in combination with MEK inhibitors356 has been established, but the drug activity is limited, and TP53 mutations may occur with long-term administration.357”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [355]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
MDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Wagner, A. J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., Johnson-Levonas, A. O., Lam, R., Meister, A. K., Russo, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7117 · Cited by 120
Self-citationActivation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Iancu-Rubin, C., Mosoyan, G., Glenn, K., Gordon, R. E., Nichols, G. L., & Hoffman, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.012 · Cited by 90
Research works printed but not linked: 10
- Wu, 1993, The p53-mdm-2 autoregulatory feedback loop, Genes Dev, 7, 1126, 10.1101/gad.7.7a.1126 · DOI · Paper page
- Bond, 2005, MDM2 is a central node in the p53 pathway: 12 years and counting, Curr Cancer Drug Targets, 5, 3, 10.2174/1568009053332627 · DOI · Paper page
- Leach, 1993, p53 mutation and MDM2 amplification in human soft tissue sarcomas, Cancer Res, 53, 2231
- Momand, 1998, The MDM2 gene amplification database, Nucleic Acids Res, 26, 3453, 10.1093/nar/26.15.3453 · DOI · Paper page
- Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 · DOI · Paper page
- Jung, 2016, TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma, Nat Commun, 7, 12609, 10.1038/ncomms12609 · DOI · Paper page
- Siu, 2014, Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors, J Clin Oncol, 32
- Demetri, 2016, Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial, J Clin Oncol, 34, 786, 10.1200/JCO.2015.62.4734 · DOI · Paper page
- Schoffski, 2016, Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial, Lancet, 387, 1629, 10.1016/S0140-6736(15)01283-0 · DOI · Paper page
- van der Graaf, 2012, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet, 379, 1879, 10.1016/S0140-6736(12)60651-5 · DOI · Paper page
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
An overview of spirooxindole as a promising scaffold for novel drug discovery
Zhou, L.-M., Qu, R.-Y., & Yang, G.-F. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1733526 · Cited by 316
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
Metadata
- Authors
- de Jonge, M., de Weger, V. A., Dickson, M. A., Langenberg, M., Le Cesne, A., Wagner, A. J., Hsu, K., Zheng, W., Macé, S., Tuffal, G., Thomas, K., & Schellens, J. H. M.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 76
- Pages
- 144-151
- ISSN
- 0959-8049
- Cited by
- 124
- References
- 8
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Sanofi
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. https://app.cochat.ai/papers/10.1016/j.ejca.2017.02.005
- The paper
- de Jonge, M., de Weger, V. A., Dickson, M. A., Langenberg, M., Le Cesne, A., Wagner, A. J., Hsu, K., Zheng, W., Macé, S., Tuffal, G., Thomas, K., & Schellens, J. H. M. (2017). A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2017.02.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.